The fundamental ethical principles that guide the conduct of biomedical research involving human subjects are embodied in the World Medical Association's Declaration of Helsinki, as revised by the 29th World Medical Assembly in Tokyo in 1975 (WHO Chronicle 1976 . In September 1981 in Manila, the Council for International Organizations of Medical Sciences (CIOMS 1982) in collaboration with WHO drew up guidelines in the form of a general survey followed by specific recommendations which were intended to indicate how the principles of the Declaration can be effectively applied, particularly in developing countries, taking into account socioeconomic circumstances, national administrative arrangements and legal provisions.
At a meeting in October 1982, held by the Medico-Pharmaceutical Forum together with the Library (Scientific Research) Section of the Royal Society of Medicine, and chaired by Dr George Birdwood, Dr John Dunne, Senior Medical Officer, Pharmaceuticals, WHO, was invited to summarize the proposed guidelines, to respond to comments from invited discussants and to join in a general discussion.
Dr Dunne focused his remarks on the special difficulties encountered in the developing world when carrying out medical research and protecting the welfare -and rights of individual subjects. With widespread endemic tropical diseases there was great emphasis on the need for community-based projects, which by their very nature might bring about incidental infringement of individual liberties; compulsory vaccination, vector-control programmes and the addition of minerals or vitamins to water supplies were examples of this. Nevertheless, all possible means should be used to inform the community of the aims and hazards of research. Externallysponsored research by pharmaceutical companies posed special difficulties through lack of understanding of local customs, because the benefits of such research might not be apparent locally, causing disillusionment, and due to the difficulty in obtaining proper compensation for incidental injury.
The subject of compensation was admittedly a difficult one, particularly when there was no negligence. It was very unlikely that there would be any local arrangements for compensating a subject taking part in a research study, and 'Report of joint meeting of the Library (Scientific Research) Section and the Medico-Pharmaceutical Forum, 28 October 1982. Accepted 10 June 1983 0141-0768/83/121075-02/$01.00 therefore where the research was sponsored by pharmaceutical manufacturers it was desirable that they should assume some responsibility in the case of accidents.
As the first discussant, Professor Charles George (Southampton) made a number of points. Quite apart from the issue of informed consent, a study had to be scientifically sound; otherwise it was unethical ab initio. The soundness or otherwise of the study might not be looked at so critically in the developing world, and time constraints might make it difficult for all the relevant data to be carefully scrutinized. It was therefore vital for the investigator to satisfy himself of the scientific objectivity of the study, and that all significant findings which would help him to make the decision should be fully disclosed. The problem of obtaining meaningful informed consent was even more difficult in developing countries because of inadequate comprehension, local differences in customs, etc. One had to be careful to distinguish between what one was allowed to do (particularly in children, the elderly and the mentally handicapped) and what it was ethical to do. Legislation and regulations were unlikely to solve problems.
The second discussant, Dr John Griffin (DHSS), emphasized the great variability in the standards of scrutiny in different developing countries, which ranged from careful scientific assessment to 'rubber stamping'. The assessment of the risks and benefits of a particular piece of research would be different in different countries and certainly between the developed and the developing world. It was therefore important to have some review body independent of the investigator and the pharmaceutical company to make the relevant judgments.
The third discussant, Dr Eric Snell (ABPI), welcomed the proposed guidelines, but considered that important messages were being obscured by duplication and some ambiguity between the general survey, which reviewed the current situation, and the proposed guidelines.
Also it should be clear that the purpose was to encourage research rather than to obstruct it. Clearly every effort should be made to ensure that any benefits of research had local as well as international impact, but it might be totally impractical to maintain research teams with their equipment after a study was concluded. Ethics committees provided an important safeguard of patients' interests provided they worked smoothly and did not simply add to the weight of bureaucracy. With regard to compensation, it © 1983 The Royal Society of Medicine was impossible for the pharmaceutical industry to give blanket indemnity for injuries sustained by patients, since they had no control over many aspects of the conduct of a trial and the possibility of investigator negligence could not be ignored. Nevertheless, the industry was conscious of its responsibilities and the fact that subjects harmed by drugs in clinical trials were unlikely to be compensated from other sources. The general discussion highlighted the difficulties inherent in research projects in the developing world, e.g. a clinical trial of the management of snake bites! The 'safari' nature of some types of research inevitably meant that medical advances or benefits were not always perceived by the local communities; this was often true of nutritional research. The structure of society in some developing countries meant that special safeguards were needed for important subgroups such as children, the mentally handicapped, pregnant women, unconscious or severely ill patients, the elderly, prisoners, and the very poor. The danger of exploitation was great and the concept of individual consent very difficult to apply in a meaningful way.
It was clearly important to involve local investigators who were of high quality, who were adequately supplied with the relevant and informative documentation, particularly about potential drug toxicity, and who were capable, with or without guidance, of translating it to the needs of the trial situation. Preventive medicine in occupational groups: medical and management approaches in industry and the armed forces' Not many years ago 'industrial medicine' was largely restricted to factories and workshops and the emphasis was on first aid, toxicology and environmental controls, personal protection and rehabilitation. 'Occupational health' has gradually expanded to cover most occupations including agriculture, commerce and multiple stores, the civil service, the armed forces and recently, not before time, the National Health Service and local authorities. The emphasis has shifted as well, to include the promotion of mental as well as physical health and good human relations, periodic health checks and screening, studies of sickness absence and epidemiology and health education.
This meeting was organized to show that even for such diverse occupations as soldier and saleswoman, the same principles of health care are provided by good management and physicians alike. This may not be very different from the paternalistic care of employees originated in the last century by John Wood of Bradford, the Quaker employers like Rowntree and Fry's or by Boots, but the scale and scope of safety, health and welfare services has widened and environmental and psychological stresses have undoubtedly increased with modem technology, both in the armed forces and in commerce. .At this meeting the thriving trading firm Marks & Spencer, and the nationalized medical service of the Army were described, both having a well established service of personnel management and preventive medicine.
Lord Sieff of Brimpton, the Chairman of Marks & Spencer, considered that good health maintenance and a contented workforce are the responsibility of managers and supervisors as much as doctors and nurses. The essential philosophy of the company is good human relations and good communications. It was his feeling that a dynamic free enterprise sector with freedom of speech, thought and action, is essential if democracy as we understand it is to survive.
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